Tech Company Financing Transactions
Be Biopharma Funding Round
On 1/15/2025, Be Biopharma raised $92 million in Series C funding from Nextech, Alta Partners and Arch Venture Partners.
Transaction Overview
Company Name
Announced On
1/15/2025
Transaction Type
Venture Equity
Amount
$92,000,000
Round
Series C
Investors
Proceeds Purpose
The company intends to use the funds to generate clinical proof-of-concept for BE-101 in the ongoing BeCoMe-9 Phase 1/2 clinical trial for people with hemophilia B and to advance BE-102 for the treatment of hypophosphatasia to the clinic.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 Kendall Sq. B200 # 001
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Overview
Be Bio is a leader in developing engineered B cells as a new category of cellular medicines. B cells are one of the most unique and versatile populations of cells in the body, playing a key role in humoral immunity and in modulating immune cell behavior in tumors and chronically inflamed tissues.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Steinberg
Co-Founder
Lea Hachigian
President
Aleks Radovic-Moreno
Browse more venture capital transactions:
Prev: 1/15/2025: Lyteflo venture capital transaction
Next: 1/15/2025: Reeco venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on tech company VC transactions. VC transactions reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs